Auto-injectors containing the active ingredient epinephrine are lifesaving for allergy sufferers.
Mylan received extensive criticism for exponential price increases. As reported in Bloomberg, James Baker, chief executive officer of patient-advocacy group Food Allergy Research & Education (FARE) said more than 400 patients in 45 states have expressed difficulty filling prescriptions for allergy devices and other auto-injectors containing the active ingredient epinephrine since May 2. Most patients told the group that they haven’t been able to obtain the devices at all, while others said they have had to wait several weeks to get one, Baker said. FARE developed a survey to track problems with accessing allergy-shot devices.
Read the conflicting stories from the FDA and The American Society of Health-System Pharmacists in Bloomberg.